• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Adicet Bio Inc.

    2/27/24 4:28:31 PM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACET alert in real time by email
    SC 13G 1 ACET_SC13G.htm SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G
    Under the Securities Exchange Act of 1934

    ADICET BIO, INC.
    (Name of Issuer)

    COMMON STOCK, PAR VALUE $0.0001 PER SHARE
    (Title of Class of Securities)

    007002108
    (CUSIP Number)

    FEBRUARY 23, 2024
    (Date of event which requires filing of this statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

         o Rule 13d-1(b)

         þ Rule 13d-1(c)

         o Rule 13d-1(d)

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the notes).



                         
    CUSIP No.
     
    007002108

    SCHEDULE 13G

    Page  
    2
      of   
    10

    1
     NAMES OF REPORTING PERSONS
     
     Millennium Management LLC
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   o
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     3,946,142
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     3,946,142
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     3,946,142
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     5.2%
    12 TYPE OF REPORTING PERSON

     
    OO


                         
    CUSIP No.
     
    007002108

    SCHEDULE 13G

    Page  
    3
      of   
    10

    1
     NAMES OF REPORTING PERSONS
     
     Millennium Group Management LLC
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   o
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     3,946,142
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     3,946,142
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     3,946,142
    10  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     5.2%
    12 TYPE OF REPORTING PERSON

     
    OO


                         
    CUSIP No.
     
    007002108

    SCHEDULE 13G

    Page  
    4
      of   
    10

    1
     NAMES OF REPORTING PERSONS
     
     Israel A. Englander
    2
     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
     (a)   o
     (b)   o
    3
     SEC USE ONLY
    4
     CITIZENSHIP OR PLACE OF ORGANIZATION

     United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5
     SOLE VOTING POWER

     -0-
    6
     SHARED VOTING POWER

     3,946,142
     
    7
     SOLE DISPOSITIVE POWER

     -0-
     
    8
     SHARED DISPOSITIVE POWER

     3,946,142
     
    9
     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     3,946,142
    10
     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     o
    11
     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     5.2%
    12
     TYPE OF REPORTING PERSON

     IN

                         
    CUSIP No.
     
    007002108

     SCHEDULE 13G

    Page  
    5
      of   
    10
     
    Item 1.    
     
    (a) Name of Issuer:
     
       
     
      Adicet Bio, Inc.
     
       
     
    (b) Address of Issuer’s Principal Executive Offices:
     
       
     
     

    200 Berkeley Street, 19th Floor
    Boston, Massachusetts 02116

         
    Item 2.
    (a) Name of Person Filing:
     
    (b) Address of Principal Business Office:
     
    (c) Citizenship:
         
     
      Millennium Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: Delaware
     
       
     
      Millennium Group Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: Delaware
     
       
     
      Israel A. Englander
    c/o Millennium Management LLC
    399 Park Avenue
    New York, New York 10022
    Citizenship: United States
     
       
      (d) Title of Class of Securities:
    common stock, par value $0.0001 per share ("Common Stock")
     
      (e) CUSIP Number:
    007002108
     
     

    Item 3.  If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:

     
      (a)   o   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
                 
     
      (b)   o   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
                 
     
      (c)   o   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
                 
     
      (d)   o   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
                 
     
      (e)   o   An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
                 
     
      (f)   o    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

                         
    CUSIP No.
     
    007002108

     SCHEDULE 13G

    Page  
    6
      of   
    10
                 
     
      (g)   o   A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
                 
     
      (h)   o   A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
                 
     
      (i)   o   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
                 
     
      (j)   o   Group, in accordance with §240.13d-1(b)(1)(ii)(J).

    Item 4. Ownership

       Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount Beneficially Owned:

       See response to Item 9 on each cover page.

    (b) Percent of Class:   

       See response to Item 11 on each cover page.

     (c) Number of shares as to which such person has:

    (i) Sole power to vote or to direct the vote

       See response to Item 5 on each cover page.


                         
    CUSIP No.
     
    007002108

     SCHEDULE 13G

    Page  
    7
      of   
    10

    (ii) Shared power to vote or to direct the vote

       See response to Item 6 on each cover page.

    (iii) Sole power to dispose or to direct the disposition of

       See response to Item 7 on each cover page.

    (iv) Shared power to dispose or to direct the disposition of

       See response to Item 8 on each cover page.

       The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC). The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.

    Item 5. Ownership of Five Percent or Less of a Class

       If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

        Not applicable.

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

        Not applicable.

    Item 8. Identification and Classification of Members of the Group

        See Exhibit I.

    Item 9. Notice of Dissolution of Group

        Not applicable.

    Item 10. Certification 

       By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


                         
    CUSIP No.
     
    007002108

    SCHEDULE 13G

    Page  
    8
      of   
    10

    Exhibits:

    Exhibit I:  Joint Filing Agreement, dated as of February 26, 2024, by and among Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander.


                         
    CUSIP No.
     
    007002108

    SCHEDULE 13G

    Page  
    9
      of   
    10
                         
         

    SIGNATURE

                 

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information with respect to it set forth in this statement is true, complete, and correct.

    Dated: February 26, 2024

    MILLENNIUM MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM GROUP MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    /s/ Israel A. Englander

    Israel A. Englander



                         
    CUSIP No.
     
    007002108

    SCHEDULE 13G

    Page  
    10
      of   
    10
                         
          EXHIBIT I              
                         
          JOINT FILING AGREEMENT              

    This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, par value $0.0001 per share, of Adicet Bio, Inc. will be filed on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

    Dated: February 26, 2024

    MILLENNIUM MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    MILLENNIUM GROUP MANAGEMENT LLC

    By: /s/Gil Raviv

    Name: Gil Raviv
    Title:  Global General Counsel

     

    /s/ Israel A. Englander

    Israel A. Englander


    Get the next $ACET alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACET

    DatePrice TargetRatingAnalyst
    9/30/2024$7.00Buy
    Guggenheim
    9/11/2024Buy → Neutral
    H.C. Wainwright
    6/27/2023Buy → Neutral
    Guggenheim
    6/27/2023Mkt Outperform → Mkt Perform
    JMP Securities
    6/1/2023$20.00 → $6.00Overweight → Neutral
    JP Morgan
    9/21/2022$23.00Overweight
    JP Morgan
    3/31/2022$28.00Outperform
    SMBC Nikko
    3/8/2022$30.00Buy
    Truist Securities
    More analyst ratings

    $ACET
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates

    Actively enrolling patients with lupus nephritis (LN), systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) in Phase 1 clinical trial of ADI-001 in autoimmune diseases On track to report preliminary clinical data for ADI-001 in 2H/2025 Enrollment now open for patients with idiopathic inflammatory myopathy (IIM), stiff person syndrome (SPS) and anti-neutrophil cytoplasmic autoantibody associated vasculitis (AAV) Advancing development of ADI-212, an optimized next-generation gene-edited and armored clinical candidate designed to enhance potency in solid tumors and to deliver multiple anti-tumor mechanisms of action to the tumor microenvironment Adicet Bio, Inc. (NASDAQ:ACET

    8/7/25 4:01:00 PM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference

    Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the 45th Annual Canaccord Genuity Growth Conference being held from August 12-14, 2025 in Boston. Details of the event are as follows: Date: Tuesday, August 12, 2025 Time: 1:30 p.m. ET The live audio webcast can be accessed on the Investors section of Adicet Bio's website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation. About Adicet Bio, Inc. Adic

    8/5/25 7:00:00 AM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adicet Bio Announces First Systemic Sclerosis (SSc) Patient Dosed in Ongoing Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases

    Phase 1 clinical trial of ADI-001 in autoimmune diseases actively enrolling patients with lupus nephritis (LN), systemic lupus erythematosus (SLE) and SSc Preliminary clinical data from Phase 1 trial of ADI-001 in autoimmune diseases expected in 2H/2025 Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that the first systemic sclerosis (SSc) patient has been dosed in the second cohort of the Phase 1 clinical trial evaluating ADI-001 in autoimmune diseases. "We are pleased with the continued momentum of our Phase 1 trial of ADI-001 in autoimmune di

    7/24/25 7:00:00 AM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACET
    SEC Filings

    View All

    SEC Form 10-Q filed by Adicet Bio Inc.

    10-Q - Adicet Bio, Inc. (0001720580) (Filer)

    8/7/25 4:05:01 PM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adicet Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Adicet Bio, Inc. (0001720580) (Filer)

    8/7/25 4:03:13 PM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Adicet Bio Inc.

    S-8 - Adicet Bio, Inc. (0001720580) (Filer)

    7/25/25 4:01:42 PM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACET
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Klickstein Lloyd was granted 5,900 shares, increasing direct ownership by 6% to 108,566 units (SEC Form 4)

    4 - Adicet Bio, Inc. (0001720580) (Issuer)

    6/13/25 4:09:59 PM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Chodakewitz Jeffrey was granted 5,900 shares, increasing direct ownership by 50% to 17,700 units (SEC Form 4)

    4 - Adicet Bio, Inc. (0001720580) (Issuer)

    6/13/25 4:08:41 PM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Dubin Steve was granted 5,900 shares, increasing direct ownership by 35% to 22,700 units (SEC Form 4)

    4 - Adicet Bio, Inc. (0001720580) (Issuer)

    6/13/25 4:07:17 PM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACET
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Orbimed Advisors Llc bought $7,500,000 worth of shares (3,125,000 units at $2.40) (SEC Form 4)

    4 - Adicet Bio, Inc. (0001720580) (Issuer)

    1/26/24 7:14:22 PM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gordon Carl L bought $7,500,000 worth of shares (3,125,000 units at $2.40) (SEC Form 4)

    4 - Adicet Bio, Inc. (0001720580) (Issuer)

    1/26/24 7:13:05 PM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schor Chen bought $15,150 worth of shares (11,000 units at $1.38), covered exercise/tax liability with 23,208 shares and sold $15,291 worth of shares (11,000 units at $1.39), decreasing direct ownership by 13% to 153,761 units (SEC Form 4)

    4 - Adicet Bio, Inc. (0001720580) (Issuer)

    10/2/23 8:16:14 PM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACET
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Adicet Bio Inc.

    SC 13G/A - Adicet Bio, Inc. (0001720580) (Subject)

    11/14/24 5:46:11 PM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Adicet Bio Inc.

    SC 13G/A - Adicet Bio, Inc. (0001720580) (Subject)

    11/14/24 4:05:07 PM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Adicet Bio Inc.

    SC 13G/A - Adicet Bio, Inc. (0001720580) (Subject)

    11/14/24 4:00:05 PM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACET
    Financials

    Live finance-specific insights

    View All

    Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024

    Expanding clinical development of ADI-001 into autoimmune diseases following clearance of Investigational New Drug Application (IND); plan to initiate Phase 1 clinical study in 2Q 2024 Focusing enrollment on mantle cell lymphoma (MCL) in ongoing ADI-001 Phase 1 clinical trial given favorable complete response (CR) rate, durability, and safety ADI-001 clinical update expected 2H 2024 ADI-270 IND submission in renal cell carcinoma expected in 2Q 2024 Updated cash runway into 2H 2025 Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and autoimmune diseases, today provided corporate upda

    1/4/24 7:00:00 AM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adicet Bio to Host Conference Call to Provide Updates on its Clinical Pipeline and Corporate Outlook

    Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that the Company will host a conference call and webcast presentation on Thursday, January 4, 2024 at 8:00am ET to provide an update on its clinical pipeline and corporate outlook. Conference Call and Webcast Event The live webcast of the presentation can be accessed by registering under "Presentations & Events" in the investors section of the Company's website at https://www.adicetbio.com. Upon registration, all participants will receive a confirmation email with a unique passcode to provide access to the webcast event. To

    1/3/24 4:01:00 PM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)

    ADI-001 demonstrated 71% overall response rate (ORR) and 63% complete response (CR) rate across all dose levels in patients with median 4 prior lines of therapy; 50% of patients enrolled had previously progressed on anti-CD19 chimeric antigen receptor T cell (CAR T) therapy 83% ORR and 67% CR rate observed in heavily pre-treated patients who had progressed on prior CAR T Six-month CR rate consistent with autologous CAR T cell therapy Favorable safety with no significant incidence of CRS (cytokine release syndrome) or ICANS (immune effector cell associated neurotoxicity syndrome) Robust pharmacokinetic profile in dose level 4 (DL4) with Cmax and Day 28 persistence exceeding approved

    6/26/23 4:00:00 PM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACET
    Leadership Updates

    Live Leadership Updates

    View All

    Adicet Bio Appoints Michael Grissinger to the Board of Directors

    --Mr. Grissinger brings more than four decades of leadership experience in pharmaceutical business development and strategic transactions-- Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Michael Grissinger to its Board of Directors. Mr. Grissinger brings more than four decades of experience in business development, strategy, and M&A leadership roles at global pharmaceutical companies. "We are honored to welcome Michael to our Board of Directors," said Chen Schor, President and Chief Executive Officer of Adicet Bio. "His extensive

    4/17/25 7:00:00 AM ET
    $ACET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer

    Dr. Maltzman Brings Oncology and Autoimmune Experience in All Stages of Drug Development, from Early-Stage Research to Successful Regulatory Approvals and Commercialization Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Julie Maltzman, M.D. as Chief Medical Officer, effective January 13, 2025. Dr. Maltzman will lead the Adicet clinical development strategy to advance Adicet's robust autoimmune and oncology pipeline. "We are incredibly pleased to welcome Julie to the Adicet team. Her vast experience in successfully leading the c

    12/18/24 7:00:00 AM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors

    Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Lloyd Klickstein, M.D., Ph.D. to its Board of Directors. "We are pleased to welcome Dr. Klickstein to our Board of Directors," said Chen Schor, President and Chief Executive Officer of Adicet Bio. "Dr. Klickstein's expertise in rheumatology and immunology, proven track record in drug development and his scientific knowledge of our gamma delta T cell platform as a former executive at Adicet will be very valuable as we progress our autoimmune programs across multiple indications. I loo

    8/19/24 7:00:00 AM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACET
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim resumed coverage on Adicet Bio with a new price target

    Guggenheim resumed coverage of Adicet Bio with a rating of Buy and set a new price target of $7.00

    9/30/24 8:04:57 AM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adicet Bio downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Adicet Bio from Buy to Neutral

    9/11/24 7:31:19 AM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adicet Bio downgraded by Guggenheim

    Guggenheim downgraded Adicet Bio from Buy to Neutral

    6/27/23 10:07:31 AM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care